Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 4/17/2020: Initial approval in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Based on HER2CLIMB)
History of changes in EMA indication
- 2/11/2021: Initial marketing authorization as Tukysa.
Also known as
- Code name: ARRY-380, ONT-380
- Generic name: irbinitinib
- Brand name: Tukysa